• Magnetic Nano-Antibodies Enable In Vivo CAR-T-Mimicry for Tu

  2026-05-20

  This study reports the development of a magnetic bispecific nano-antibody platform (M-BiNanoAb) for in vivo generation and guidance of CAR-T-mimicking cells, overcoming major barriers in solid tumor immunotherapy. The results highlight a new strategy to reprogram circulating T cells and precisely direct their migration into tumors, offering a promising alternative to traditional ex vivo CAR-T cell engineering.

• EZ Cap™ Cy5 EGFP mRNA (5-moUTP): Dual-Reporter mRNA Assays

  2026-05-19

  Unlock dual fluorescence for real-time mRNA delivery and translation efficiency assays in advanced gene therapy research. EZ Cap™ Cy5 EGFP mRNA (5-moUTP) from APExBIO streamlines quantitative workflows, minimizes innate immune activation, and enables robust functional validation in next-generation nanoparticle optimization.

• Lipid Nanoparticle Delivery of ABE8e Corrects COL7A1 in DEB

  2026-05-19

  This study demonstrates the efficient delivery of adenine base editor ABE8e using lipid nanoparticles (LNPs) to correct pathogenic COL7A1 mutations in dystrophic epidermolysis bullosa (DEB) fibroblasts in vitro. These findings highlight a promising gene editing strategy for inherited skin diseases and inform future workflows involving mRNA and protein tracking technologies.

• EZ Cap™ Cre mRNA (m1Ψ): High-Efficiency Gene Editing Workflo

  2026-05-18

  EZ Cap™ Cre mRNA (m1Ψ) delivers robust, low-immunogenicity Cre recombinase expression for gene editing and functional studies. Its Cap 1 and m1Ψ modifications support advanced mRNA delivery and streamline in vitro and in vivo protocols—backed by the reliability of APExBIO.

• Biotin-XX Tyramide Reagent: Precision Cell Surface Labeling

  2026-05-18

  Biotin-XX Tyramide Reagent empowers highly selective, membrane-impermeant cell surface protein labeling for advanced tyramide signal amplification workflows. Its optimized linker and HRP-catalyzed chemistry deliver unmatched sensitivity in spatial proteomics, as demonstrated by leading-edge proximity labeling techniques.

• Substance P in Pain Transmission Research: Protocols & Insig

  2026-05-17

  Unlock the full experimental potential of Substance P—a gold-standard tachykinin neuropeptide—for pain, immune, and neuroinflammation research. This article delivers actionable workflows, troubleshooting strategies, and cross-validated spectral analytics to maximize reproducibility and data clarity in CNS studies.

• DMH1: A Selective ALK2 Inhibitor for Organoid and NSCLC Rese

  2026-05-16

  DMH1 stands out as a highly selective ALK2 inhibitor, enabling precise BMP pathway modulation in both organoid engineering and non-small cell lung cancer studies. This article unpacks practical workflows, troubleshooting strategies, and novel applications, translating recent high-impact findings into actionable laboratory protocols.

• 10 mM dNTP Mixture: Precision in DNA Synthesis & Delivery

  2026-05-15

  The 10 mM dNTP (2'-deoxyribonucleoside-5'-triphosphate) mixture enables reliable, high-fidelity DNA synthesis and advanced molecular workflows. Its equimolar formulation ensures reproducibility in PCR, qPCR, and DNA sequencing—crucial for both fundamental research and cutting-edge lipid nanoparticle studies.

• Firefly Luciferase mRNA: Applied Workflows & Troubleshooting

  2026-05-15

  EZ Cap™ Firefly Luciferase mRNA (5-moUTP) by APExBIO is engineered for unmatched sensitivity and immune evasion in bioluminescent reporter assays. This article delivers protocol-driven guidance, real-world troubleshooting, and expert insights for maximizing mRNA delivery and translation efficiency in both in vitro and in vivo research.

• Unveiling Dual-Fluorescence mRNA: EZ Cap™ Cy5 EGFP mRNA (5-m

  2026-05-14

  Explore the scientific foundation and advanced applications of EZ Cap™ Cy5 EGFP mRNA (5-moUTP), a Cy5-labeled mRNA optimized for real-time delivery and translation efficiency assays. Discover how its unique modifications enhance assay precision and provide new insights beyond existing mRNA delivery content.

• L-NMMA Acetate (SKU B6444): NOS Pathway Modulation for Relia

  2026-05-14

  This authoritative guide explores common laboratory challenges in cell viability, proliferation, and cytotoxicity assays, demonstrating how L-NMMA acetate (SKU B6444) delivers reproducible, data-backed solutions. Drawing on peer-reviewed research and highlighting APExBIO’s quality standards, the article provides actionable workflow recommendations for maximizing nitric oxide pathway modulation in biomedical experiments.

• Poly(2-ethyl-2-oxazoline) Lipids Advance LNP Gene Delivery

  2026-05-13

  This study demonstrates that poly(2-ethyl-2-oxazoline) (PEtOx)-based lipids can effectively replace poly(ethylene glycol) (PEG)-lipids in lipid nanoparticle (LNP) formulations for mRNA delivery. The work addresses the increasing immunogenicity of PEG by providing a detailed comparison of PEtOx- and PEG-LNPs, revealing equal or superior transfection efficiency and reduced immunoreactivity, with significant implications for gene therapy and vaccine delivery systems.

• Defining the Complete Biosynthesis of Nicotine in Plants

  2026-05-13

  Chang et al. (2026) resolve the full enzymatic pathway of plant nicotine biosynthesis, identifying key glycosylation and transport mechanisms that enable efficient synthesis and compartmentalization. These insights unlock new strategies for metabolic engineering and biochemical investigation in both native and heterologous systems.

• Tc3-Induced Pyroptosis as a Strategy for Hepatic Carcinoma T

  2026-05-12

  The reference study introduces Tc3, a thiazolidinedione-substituted indole analogue, as a potent inducer of gasdermin E-mediated pyroptosis in hepatic carcinoma. By elucidating Tc3's mechanism and synergy with cisplatin and anti-PD-1, the research advances therapeutic strategies for aggressive liver cancers and provides a rationale for integrating advanced apoptosis and DNA fragmentation assays.

• Spleen-Targeted mRNA Vaccine Induces TLS in Hepatocellular C

  2026-05-12

  Lin et al. introduce a spleen-targeted neoantigen mRNA vaccine (STNvac) that elicits robust ISG15+ CD8+ T cell responses and triggers tertiary lymphoid structure (TLS) formation in hepatocellular carcinoma models. Their findings clarify mechanisms of immune activation and offer new directions for organ-targeted mRNA immunotherapy in otherwise refractory solid tumors.

668 records 11/45 page Previous Next First page 上5页 1112131415 下5页 Last page